US2018346416A1PendingUtilityA1

N-substituted benzamides and methods of use thereof

Assignee: GENENTECH INCPriority: Jul 6, 2012Filed: Aug 7, 2018Published: Dec 6, 2018
Est. expiryJul 6, 2032(~5.9 yrs left)· nominal 20-yr term from priority
A61P 9/06A61P 9/00A61P 5/14A61P 39/02A61P 9/10A61P 43/00A61P 29/02A61P 31/18A61P 25/06A61P 25/22A61P 29/00A61P 3/12A61P 25/18A61P 25/04A61P 25/02A61P 25/08A61P 25/24A61P 35/00C07D 277/62C07D 215/20C07D 401/12A61K 31/4439C07D 213/74C07D 217/02A61P 13/10C07C 307/06A61K 31/444C07C 2601/04A61P 25/00C07D 209/08C07D 413/12C07D 213/64C07D 405/12C07D 231/56C07D 213/63A61P 21/00A61K 31/44A61P 1/00C07D 205/04C07D 277/34A61P 19/02C07D 305/08C07D 277/24A61P 1/04C07D 213/69A61P 17/04A61P 21/02A61P 1/02A61P 11/00
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described herein.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of treating pain, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein said pain is neuropathic pain, inflammatory pain, visceral pain, cancer pain, chemotherapy pain, trauma pain, surgical pain, post-surgical pain, childbirth pain, labor pain, chronic pain, persistent pain, peripherally mediated pain, centrally mediated pain, chronic headache, migraine headache, sinus headache, tension headache, phantom limb pain, or dental pain, or a combination thereof. 
     
     
         3 . The method of  claim 1 , wherein said pain is associated with neurogenic bladder, ulcerative colitis, or peripheral nerve injury, or a combination thereof. 
     
     
         4 . The method of  claim 1 , wherein said pain is associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, post-herpetic neuralgia, eudynia, heat sensitivity, tosarcoidosis, irritable bowel syndrome, Crohns disease, pain associated with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), diabetic neuropathy, peripheral neuropathy, arthritis, rheumatoid arthritis, osteoarthritis, atherosclerosis, paroxysmal dystonia, myasthenia syndromes, myotonia, malignant hyperthermia, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, hypothyroidism, bipolar depression, anxiety, schizophrenia, sodium channel toxin related illnesses, familial erythromelalgia, primary erythromelalgia, familial rectal pain, cancer, epilepsy, partial and general tonic seizures, restless leg syndrome, arrhythmias, fibromyalgia, neuroprotection under ischaemic conditions cause by stroke or neural trauma, tachy-arrhythmias, atrial fibrillation and ventricular fibrillation.

Join the waitlist — get patent alerts

Track US2018346416A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.